xaluritamig   Click here for help

GtoPdb Ligand ID: 13718

Synonyms: AMG 509 | AMG-509 | AMG509
Compound class: Antibody
Comment: Xaluritamig (AMG 509) is a humanised bispecific monoclonal antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1; on prostate tumour cells) and CD3e (on T cells) [2]. It is a bispecific T cell engager (BiTE) class monoclonal, that was designed for therapeutic use against prostate cancer. Engaging these two surface molecules facilitates immune mediated killing of STEAP1-expressing cancer cells. Cryo-electron microscopy reveals that the anti-STEAP1 Fab domain of xaluritamig binds to a STEAP1 homotrimer.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Xaluritamig is under evaluation as a monotherapy and in combination with other antitumour drugs, to determine safety and efficacy in advanced prostate cancer. Results from a first-in-human study, exploring xaluritamig monotherapy in patients with metastatic castration-resistant prostate cancer, were published in early 2024 [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04221542 Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 1 Interventional Amgen 1
NCT06691984 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer Phase 3 Interventional Amgen